West Pharma falls as it expects lower growth from drug components business

Shares of medical equipment maker West Pharmaceuticals WST.N fall 3.7% to $210.19 in morning trade

Company expects its HVP components business to grow mid-single digits instead of mid-to-high single digits, as it previously forecast

Forecast cut came as one of WST's customers switched the type of component they were purchasing, which can currently only be supplied from one manufacturing facility, while the previous one could be sourced from multiple facilities

This results in some stock-outs / delay in shipping this product to the customer - Nephron Research

The business includes products to improve shelf life of packaged drugs, among others

Company raised its annual adj EPS forecast to $6.15 to $6.35, up from $6 to $6.20

WST reports Q1 adj. profit of $1.45/share, vs analysts' estimate of $1.23/share

As of last close, WST stock down 33.4% YTD